{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T16:17:05Z","timestamp":1710346625777},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,14]]},"DOI":"10.7759\/cureus.54206","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T01:12:16Z","timestamp":1707959536000},"source":"Crossref","is-referenced-by-count":0,"title":["Role of Portosystemic Shunt and Portal Vein Stent in Managing Portal Hypertension Due to Hematological Diseases"],"prefix":"10.7759","author":[{"given":"Ji Hoon","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee-Chul","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Sung","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Won","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Won","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Kew","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho-Jong","family":"Chun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Suk","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pil Soo","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - renewing consensus in portal hypertension","volume":"76","author":"de Franchis R","year":"2022","unstructured":"de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C. Baveno VII - renewing consensus in portal hypertension. J Hepatol. 2022, 76:959-974. 10.1016\/j.jhep.2021.12.022","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2013.12.001","article-title":"Pathophysiology of portal hypertension","volume":"18","author":"Iwakiri Y","year":"2014","unstructured":"Iwakiri Y. Pathophysiology of portal hypertension. Clin Liver Dis. 2014, 18:281-291. 10.1016\/j.cld.2013.12.001","journal-title":"Clin Liver Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1586\/egh.12.83","article-title":"Assessing portal hypertension in liver diseases","volume":"7","author":"Berzigotti A","year":"2013","unstructured":"Berzigotti A, Seijo S, Reverter E, Bosch J. Assessing portal hypertension in liver diseases. Expert Rev Gastroenterol Hepatol. 2013, 7:141-155. 10.1586\/egh.12.83","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0414","article-title":"Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: still some shades of grey","volume":"29","author":"Rodrigues SG","year":"2023","unstructured":"Rodrigues SG. Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: still some shades of grey. Clin Mol Hepatol. 2023, 29:110-112. 10.3350\/cmh.2022.0414","journal-title":"Clin Mol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2014.04.004","article-title":"Clinical features of patients with Philadelphia \u2014\u00a0negative myeloproliferative neoplasms complicated by portal hypertension","volume":"15","author":"Yan M","year":"2015","unstructured":"Yan M, Geyer H, Mesa R, et al.. Clinical features of patients with Philadelphia \u2014\u00a0negative myeloproliferative neoplasms complicated by portal hypertension. Clin Lymphoma Myeloma Leuk. 2015, 15:e1-e5. 10.1016\/j.clml.2014.04.004","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.22733","article-title":"An unusual case of myelodysplastic syndrome with intrahepatic extramedullary hematopoiesis leading to liver failure","volume":"14","author":"Ternes L","year":"2022","unstructured":"Ternes L, Giangiacomo F, Nassif I. An unusual case of myelodysplastic syndrome with intrahepatic extramedullary hematopoiesis leading to liver failure. Cureus. 2022, 14:e22733. 10.7759\/cureus.22733","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2021.0239","article-title":"The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: advantages and pitfalls","volume":"28","author":"Lee HL","year":"2022","unstructured":"Lee HL, Lee SW. The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: advantages and pitfalls. Clin Mol Hepatol. 2022, 28:121-134. 10.3350\/cmh.2021.0239","journal-title":"Clin Mol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.04.028","article-title":"TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis","volume":"79","author":"Larrue H","year":"2023","unstructured":"Larrue H, D'Amico G, Olivas P, et al.. TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis. J Hepatol. 2023, 79:692-703. 10.1016\/j.jhep.2023.04.028","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/673781","article-title":"Portal hypertension and myeloproliferative neoplasms: a relationship revealed","volume":"2013","author":"Toros AB","year":"2013","unstructured":"Toros AB, Gokcay S, Cetin G, Ar MC, Karagoz Y, Kesici B. Portal hypertension and myeloproliferative neoplasms: a relationship revealed. ISRN Hematol. 2013, 2013:673781. 10.1155\/2013\/673781","journal-title":"ISRN Hematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2019.0078","article-title":"Clinical characteristics of portal hypertension complicated by gastroesophageal varices in patients with myeloproliferative neoplasms","volume":"26","author":"Lee J","year":"2020","unstructured":"Lee J, Sung PS, Eom KS, et al.. Clinical characteristics of portal hypertension complicated by gastroesophageal varices in patients with myeloproliferative neoplasms. Clin Mol Hepatol. 2020, 26:78-82. 10.3350\/cmh.2019.0078","journal-title":"Clin Mol Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15811","article-title":"A prospective, multicentre study in acute non-cirrhotic, non-malignant portal vein thrombosis: comparison of medical and interventional treatment","volume":"52","author":"R\u00f6ssle M","year":"2020","unstructured":"R\u00f6ssle M, Bettinger D, Trebicka J, et al.. A prospective, multicentre study in acute non-cirrhotic, non-malignant portal vein thrombosis: comparison of medical and interventional treatment. Aliment Pharmacol Ther. 2020, 52:329-339. 10.1111\/apt.15811","journal-title":"Aliment Pharmacol Ther"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-022-03411-w","article-title":"Interventional recanalization therapy in patients with non-cirrhotic, non-malignant portal vein thrombosis: comparison between transjugular versus transhepatic access","volume":"47","author":"Mansour N","year":"2022","unstructured":"Mansour N, \u00d6cal O, Gerwing M, et al.. Interventional recanalization therapy in patients with non-cirrhotic, non-malignant portal vein thrombosis: comparison between transjugular versus transhepatic access. Abdom Radiol (NY). 2022, 47:1177-1186. 10.1007\/s00261-022-03411-w","journal-title":"Abdom Radiol (NY)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-2980.2011.00514.x","article-title":"Diagnosis and treatment of portal hypertension secondary to myeloproliferative disorders: a report of three cases","volume":"12","author":"Zhao G","year":"2011","unstructured":"Zhao G, Wu ZY, Zhang B, Sun YW, Luo M. Diagnosis and treatment of portal hypertension secondary to myeloproliferative disorders: a report of three cases. J Dig Dis. 2011, 12:312-316. 10.1111\/j.1751-2980.2011.00514.x","journal-title":"J Dig Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13038","article-title":"Education and imaging. Hepatobiliary and pancreatic: a rare cause of portal hypertension","volume":"31","author":"Torres MCP","year":"2016","unstructured":"Torres MCP, Romana C, Coppo C, Zentilin P, Grillo F, Savarino V, Giannini EG. Education and imaging. Hepatobiliary and pancreatic: a rare cause of portal hypertension. J Gastroenterol Hepatol. 2016, 31:11. 10.1111\/jgh.13038","journal-title":"J Gastroenterol Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an international prognostic score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui T","year":"2012","unstructured":"Barbui T, Finazzi G, Carobbio A, et al.. Development and validation of an international prognostic score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012, 120:5128-5133. 10.1182\/blood-2012-07-444067","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67785-9.","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell PJ","year":"2005","unstructured":"Campbell PJ, Scott LM, Buck G, et al.. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005, 366:1945-1953. 10.1016\/S0140-6736(05)67785-9.","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-009-0933-y","article-title":"JAK2V617F mutation in patients with splanchnic vein thrombosis","volume":"55","author":"Xavier SG","year":"2010","unstructured":"Xavier SG, Gadelha T, Pimenta G, et al.. JAK2V617F mutation in patients with splanchnic vein thrombosis. Dig Dis Sci. 2010, 55:1770-1777. 10.1007\/s10620-009-0933-y","journal-title":"Dig Dis Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24798","article-title":"Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension","volume":"92","author":"Reilly CR","year":"2017","unstructured":"Reilly CR, Babushok DV, Martin K, et al.. Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension. Am J Hematol. 2017, 92:909-914. 10.1002\/ajh.24798","journal-title":"Am J Hematol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15148","article-title":"Portosystemic shunt is an effective treatment for complications of portal hypertension in hepatic myeloid metaplasia and improves nutritional status","volume":"42","author":"Aspite S","year":"2022","unstructured":"Aspite S, Schepis F, Roccarina D, et al.. Portosystemic shunt is an effective treatment for complications of portal hypertension in hepatic myeloid metaplasia and improves nutritional status. Liver Int. 2022, 42:419-424. 10.1111\/liv.15148","journal-title":"Liver Int"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510290302","article-title":"Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis","volume":"29","author":"Lotterer E","year":"1999","unstructured":"Lotterer E, Wengert A, Fleig WE. Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis. Hepatology. 1999, 29:632-639. 10.1002\/hep.510290302","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00094.2017","article-title":"Transjugular intrahepatic portosystemic shunt: impact on systemic hemodynamics and renal and cardiac function in patients with cirrhosis","volume":"314","author":"Busk TM","year":"2018","unstructured":"Busk TM, Bendtsen F, Poulsen JH, et al.. Transjugular intrahepatic portosystemic shunt: impact on systemic hemodynamics and renal and cardiac function in patients with cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2018, 314:G275-G286. 10.1152\/ajpgi.00094.2017","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22274","article-title":"Chronic idiopathic myelofibrosis with myeloid metaplasia presenting as refractory ascites","volume":"54","author":"Patra B","year":"2010","unstructured":"Patra B, Maheshwari A, Chandra J, Aneja S, Agarwal S, Nangia A, Seth A. Chronic idiopathic myelofibrosis with myeloid metaplasia presenting as refractory ascites. Pediatr Blood Cancer. 2010, 54:151-153. 10.1002\/pbc.22274","journal-title":"Pediatr Blood Cancer"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/BF01317043","article-title":"Ascites progressing to an abdominal mass due to extramedullary hematopoiesis in a patient with agnogenic myeloid metaplasia (AMM)","volume":"28","author":"Marshall JB","year":"1983","unstructured":"Marshall JB, Burnett DA, Anderson JC, Zetterman RK. Ascites progressing to an abdominal mass due to extramedullary hematopoiesis in a patient with agnogenic myeloid metaplasia (AMM). Dig Dis Sci. 1983, 28:912-917. 10.1007\/BF01317043","journal-title":"Dig Dis Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/s1590-8658(02)80246-8","article-title":"Role of spleen enlargement in cirrhosis with portal hypertension","volume":"34","author":"Bolognesi M","year":"2002","unstructured":"Bolognesi M, Merkel C, Sacerdoti D, Nava V, Gatta A. Role of spleen enlargement in cirrhosis with portal hypertension. Dig Liver Dis. 2002, 34:144-150. 10.1016\/s1590-8658(02)80246-8","journal-title":"Dig Liver Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/224187-role-of-portosystemic-shunt-and-portal-vein-stent-in-managing-portal-hypertension-due-to-hematological-diseases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T01:12:19Z","timestamp":1707959539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/224187-role-of-portosystemic-shunt-and-portal-vein-stent-in-managing-portal-hypertension-due-to-hematological-diseases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.54206","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,14]]}}}